Scholarlink

Introduction <p>Low-dose inhaled corticosteroids (ICS) manage mild bronchial asthma effectively. Although pressurized metered-dose inhalers (pMDI) and dry powder inhalers (DPI) demonstrate similar efficacy in moderate-to-severe asthma, their effectiveness against mild asthma remains less established. This multicenter study evaluates the efficacy of ICS-pMDI versus ICS-DPI in newly diagnosed mild asthma.</p> Methods <p>Patients (156) with newly diagnosed mild asthma were randomized to receive pMDI or DPI treatment for 4&#xa0;weeks. Evaluations included lung function, asthma control test (ACT) scores, and blood eosinophil (EOS) counts. Data were analyzed using the full analysis set (FAS) and per-protocol set (PPS).</p> Results <p>FAS analysis indicated that the pMDI group had significantly improved large airway parameters such as forced expiratory volume in 1&#xa0;s (FEV<sub>1</sub>) and forced vital capacity (FVC). PPS analysis revealed enhanced small airway function (SAF) indicators such as forced expiratory flow at 50% of forced vital capacity (FEF<sub>50%</sub>) and forced expiratory flow at 25–75% of forced vital capacity (FEF<sub>25–75%</sub>) in the pMDI group, with no significant changes in the DPI group. The pMDI group also showed greater absolute improvement in FEV<sub>1</sub>, especially in patients with baseline small airway dysfunction (SAD) or EOS ≥ 150&#xa0;cells/µL. Both groups had significantly improved ACT scores and reduced EOS counts, without significant intergroup differences. Correlation analysis revealed a positive relationship between baseline FEV<sub>1</sub> reversibility and improvements in FEV<sub>1</sub> and FEF<sub>25–75%</sub> in the pMDI group. Exacerbation rates and adverse events were similar between groups.</p> Conclusion <p>A 4-week ICS-pMDI treatment may improve both large and small airway function in patients with newly diagnosed mild asthma, with comparable symptom control, inflammation reduction, and adverse event profile to ICS-DPI. Baseline SAD, elevated EOS levels, and FEV<sub>1</sub> reversibility may predict pMDI effectiveness in improving airway function.</p> Clinical Trial Registration <p>ChiCTR2400094311, <a href="http://www.chictr.org.cn">www.chictr.org.cn</a>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of Inhaler Devices in New-Onset Mild Asthma: A Randomized Blinded Multicenter Trial

  • 期刊论文

  • 发表日期：

    2025年6月11日

查看全文
  • Yan Zhou,
  • Na Li,
  • Qi Zheng,
  • Wei Han,
  • Luqian Zhou,
  • Hui Zhao,
  • Xunchao Liu,
  • Wuping Bao,
  • Yilin Pan,
  • Yingying Zhang,
  • Chengjian Lv,
  • Huifang Cao,
  • Dang Li,
  • Changsheng Ge,
  • Hui Zhu,
  • Shilong Zhu,
  • Huahao Shen,
  • Min Zhang

摘要

Introduction

Low-dose inhaled corticosteroids (ICS) manage mild bronchial asthma effectively. Although pressurized metered-dose inhalers (pMDI) and dry powder inhalers (DPI) demonstrate similar efficacy in moderate-to-severe asthma, their effectiveness against mild asthma remains less established. This multicenter study evaluates the efficacy of ICS-pMDI versus ICS-DPI in newly diagnosed mild asthma.

Methods

Patients (156) with newly diagnosed mild asthma were randomized to receive pMDI or DPI treatment for 4 weeks. Evaluations included lung function, asthma control test (ACT) scores, and blood eosinophil (EOS) counts. Data were analyzed using the full analysis set (FAS) and per-protocol set (PPS).

Results

FAS analysis indicated that the pMDI group had significantly improved large airway parameters such as forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC). PPS analysis revealed enhanced small airway function (SAF) indicators such as forced expiratory flow at 50% of forced vital capacity (FEF50%) and forced expiratory flow at 25–75% of forced vital capacity (FEF25–75%) in the pMDI group, with no significant changes in the DPI group. The pMDI group also showed greater absolute improvement in FEV1, especially in patients with baseline small airway dysfunction (SAD) or EOS ≥ 150 cells/µL. Both groups had significantly improved ACT scores and reduced EOS counts, without significant intergroup differences. Correlation analysis revealed a positive relationship between baseline FEV1 reversibility and improvements in FEV1 and FEF25–75% in the pMDI group. Exacerbation rates and adverse events were similar between groups.

Conclusion

A 4-week ICS-pMDI treatment may improve both large and small airway function in patients with newly diagnosed mild asthma, with comparable symptom control, inflammation reduction, and adverse event profile to ICS-DPI. Baseline SAD, elevated EOS levels, and FEV1 reversibility may predict pMDI effectiveness in improving airway function.

Clinical Trial Registration

ChiCTR2400094311, www.chictr.org.cn.